Heron Therapeutics has been granted a patent for novel pharmaceutical formulations of a neurokinin-1 (NK-1) receptor antagonist for preventing post-operative nausea and vomiting. The injectable emulsion includes an emulsifier, oil, co-surfactant, and aqueous phase, with a specific ratio for effective administration. GlobalData’s report on Heron Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Heron Therapeutics, Nanoparticle drug conjugates was a key innovation area identified from patents. Heron Therapeutics's grant share as of February 2024 was 46%. Grant share is based on the ratio of number of grants to total number of patents.
Patent granted for injectable emulsion to prevent post-operative nausea
A recently granted patent (Publication Number: US11878074B2) discloses a method for preventing post-operative nausea and vomiting in a subject by administering an injectable pharmaceutical emulsion. The emulsion comprises a neurokinin-1 (NK-1) receptor antagonist, an emulsifier, an oil, a co-surfactant, and an aqueous phase. The ratio of the emulsifier to the NK-1 receptor antagonist ranges from about 18:1 to 22:1 (wt/wt %), with additional specifications on the ratios of oil to the NK-1 receptor antagonist and the percentage of emulsifier in the emulsion.
Furthermore, the patent claims specify the inclusion of dexamethasone sodium phosphate in the emulsion, along with the option of using various NK-1 receptor antagonists such as aprepitant. The method also allows for the use of specific pH modifiers like oleic acid or a buffer, with soybean oil identified as the preferred oil component. Additionally, the presence of ethanol in the emulsion is limited to less than 10 wt/wt %. These detailed claims provide a comprehensive guide for the formulation and administration of the injectable pharmaceutical emulsion to effectively prevent post-operative nausea and vomiting in subjects, showcasing a novel approach in the field of pharmaceutical interventions for post-operative care.
To know more about GlobalData’s detailed insights on Heron Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
